SPH3127 clinical trials
Also written SPH3127.
How each study uses SPH3127 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Shanghai Pharmaceuticals Holding Co., Ltd (7) · Shanghai Pharma Biotherapeutics USA Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses SPH3127 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative ColitisTerminatedPhase 2Shanghai Pharma Biotherapeutics USA Inc.NCT05019742Written as SPH3127
- Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential HypertensionCompletedPhase 3Shanghai Pharmaceuticals Holding Co., LtdNCT05359068Written as SPH3127 tablet
- Study on Human Mass Balance of SPH3127 TabletsCompletedPhase 1/2Shanghai Pharmaceuticals Holding Co., LtdNCT05593562Written as SPH3127
- Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy VolunteersCompletedPhase 1Shanghai Pharmaceuticals Holding Co., LtdNCT03128138Written as SPH3127
- Drug-drug Interaction Study of SPH3127CompletedPhase 1/2Shanghai Pharmaceuticals Holding Co., LtdNCT05359055Written as SPH3127 tablet
- Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension PatientsCompletedPhase 2Shanghai Pharmaceuticals Holding Co., LtdNCT03756103Written as SPH3127 tablet Dose 1
- The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy PeopleCompletedPhase 1Shanghai Pharmaceuticals Holding Co., LtdNCT03255993Written as SPH3127 50mg
- The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health SubjectsCompletedPhase 1Shanghai Pharmaceuticals Holding Co., LtdNCT03249753Written as SPH3127 200mg Panel A
Codes
What other systems call SPH3127 · ClinicalTrials.gg INT001377
- UNII (FDA) C2M78A9V6ZSITOKIRENConfirmed FDA, Wikidata
- Wikidata Q123913949SPH3127Confirmed FDA, Wikidata
- DrugBank DB19108One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C2M78A9V6Z | SITOKIREN | Confirmed FDA, Wikidata |
| Wikidata | Q123913949 | SPH3127 | Confirmed FDA, Wikidata |
| DrugBank | DB19108 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.